Pediatric Acute Myeloid Leukemia as Classified Using 2008 WHO Criteria

Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study

(2011) K. Nottage et al.   BLOOD

Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group

(2010) Yasuhiro Mizushima et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Prognostic Significance ofCEBPAMutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of DoubleCEBPAMutations and the Interaction WithFLT3andNPM1Mutations

(2010) Claire L. Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

(2010) Christine J. Harrison et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

(2009) P. A. Ho et al.   BLOOD

Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system

(2009) O. K. Weinberg et al.   BLOOD

Acute Myeloid Leukemia

(2009) Amy Heerema-McKenney et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

A Comparison of Two Methods for Screening CEBPA Mutations in Patients with Acute Myeloid Leukemia

(2009) Jeung-Yeal Ahn et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

(2008) B. Falini et al.   HAEMATOLOGICA

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

(2008) I H I M Hollink et al.   LEUKEMIA